Document is current
Any future updates will be listed below
-
Authors
Kirtane, Kedar https://orcid.org/0000-0003-1302-9577
Elmariah, Hany
Chung, Christine H
Abate-Daga, Daniel
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02621021 at ClinicalTrials.govnct03645928 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
https://doi.org/10.1136/jitc-2021-002595
nct03215810 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2021-sitc2021.458
492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers
https://doi.org/10.1136/jitc-2021-sitc2021.492
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
1488 A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results
https://doi.org/10.1136/jitc-2024-sitc2024.1488
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.
https://doi.org/10.1200/jco.2024.42.16_suppl.9505
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007218
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2020-000668
nct02650986 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes
https://doi.org/10.1136/jitc-2021-003082
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007218
nct03139370 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis
https://doi.org/10.1136/jitc-2023-007935
nct03912831 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
nct03970382 at ClinicalTrials.govDocuments that mention this clinical trial
Ensuring equity in the era of HLA-restricted cancer therapeutics
https://doi.org/10.1136/jitc-2022-005600
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
nct04044950 at ClinicalTrials.govDocuments that mention this clinical trial
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
712 Retrospective tumor microenvironment analysis from a personalized neoTCR-T cell therapy clinical trial and its potential applications for off-the-shelf HPV TCRs
https://doi.org/10.1136/jitc-2022-sitc2022.0712
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
820 Machine learning significantly improves neoantigen-HLA predictions utilizing > 26,000 data points from the PACTImmuneTM Database
https://doi.org/10.1136/jitc-2021-sitc2021.820
nct02706392 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
nct02414269 at ClinicalTrials.govDocuments that mention this clinical trial
Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
https://doi.org/10.1136/jitc-2020-000676
Role of immunotherapy in Ewing sarcoma
https://doi.org/10.1136/jitc-2020-000653
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
nct03873805 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
Documents that mention this clinical trial
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).
https://doi.org/10.1200/jco.2023.41.16_suppl.5019
TGM4: an immunogenic prostate-restricted antigen
https://doi.org/10.1136/jitc-2020-001649
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
309 Combining radiopharmaceutical therapy with CAR T cells to overcome the heterogeneous immunosuppressive prostate tumor microenvironment
https://doi.org/10.1136/jitc-2025-sitc2025.0309
360 Novel immunotherapy for prostate cancer combining CAR T cells and myeloid cell STAT3 inhibition
https://doi.org/10.1136/jitc-2022-sitc2022.0360
- License Information
